H.I.G.-CAPITAL
15.3.2021 12:30:05 CET | Business Wire | Press release
H.I.G. Capital (“H.I.G.“), a leading global alternative investment firm with over €35 billion of equity capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell Infinigate (the “Company”) to Bridgepoint, an international alternative asset fund management group. H.I.G. acquired a majority stake in the Company in 2017. The transaction is subject to clearance by the relevant antitrust authorities.
Infinigate, founded in 1996, is a leading specialized value-added distributor (“VAD”) for cybersecurity and cloud solutions for the SME segment. The core of Infinigate’s business is software distribution – acting as a sales multiplicator between vendors and resellers, giving market access to disruptive vendors, and providing value-added services, such as technical support, trainings, and marketing support to vendors and resellers. Infinigate focuses on strongly growing cybersecurity and cloud segments and supports its multinational software vendors in their expansion throughout Europe by providing a network of more than 10,000 resellers.
With the support of H.I.G., the Company implemented a comprehensive European expansion strategy. Infinigate benefited from H.I.G.’s substantial expertise and extensive network in the technology sector, and from its experience in successfully implementing buy and build strategies. It acquired Dutch cyber security VAD Crypsys in 2017 to expand into the Benelux markets. It subsequently acquired acmeo, a German specialist distributor for the Managed Security Service Provider (“MSSP”) segment to expand into the cloud segment. During the past four years, Infinigate‘s management successfully managed to double the Company’s revenue. Today, the Company has more than 450 employees and is present in eleven European countries – including the DACH region, Benelux, France, the UK and the Nordic countries.
David Martinez, Chairman of the Board and founder of Infinigate, said: ”The close, trusting and successful cooperation with H.I.G. was key for Infinigate to continue its exceptional success story and to tap into additional markets on the continent. Together, we have successfully transformed Infinigate and established the Company as the European leader in the field of cybersecurity solutions. I would like to thank H.I.G. for their support these past few years and look forward to accompany the Company’s next chapter with Bridgepoint, our future investor.”
Klaus Schlichtherle, CEO of Infinigate, added: “Together with H.I.G., we have succeeded in further strengthening Infinigate’s position as a leading VAD in Europe and look forward to partnering with the team at Bridgepoint to continue with our growth strategy and take the business to the next level.”
Dr. Holger Kleingarn, Managing Director at H.I.G., commented: “We are delighted that we were able to support Infinigate on its successful growth trajectory towards a true European market leader. Infinigate demonstrates H.I.G.’s ability to develop companies through a sustainable combination of organic growth and acquisitions. Infinigate is perfectly positioned for further growth on a global scale, and we wish the management team continued success in the future.”
The parties have agreed not to disclose further details of the transaction.
About Infinigate
Infinigate was founded in 1996 as the first European distributor for internet technologies. Since the turn of the millennium, Infinigate has specialized exclusively in the distribution of cyber security solutions for sustainable protection of IT networks, servers, end devices, data and applications. With the acquisition of acmeo, the security competence of the group was extended to the cloud and MSSP (Managed Security Service Providing) business. As a true VAD, Infinigate focuses on innovative and explanation-intensive solutions for enterprises and provides manufacturers and partners (resellers, IT integrators, system houses, etc.) with a range of additional services in the areas of technology, marketing and sales. After several successful market entries and acquisitions, Infinigate intends to continue its geographic expansion strategy. Today, the Infinigate Group has more than 450 employees and is represented by subsidiaries in eleven European countries (Germany, Austria, Switzerland, UK, France, Netherlands, Belgium, Sweden, Norway, Denmark and Finland). Infinigate thus covers more than 80% of the Western European cyber security market potential and has established itself as the leading value-added distributor for cyber security in Europe.
About H.I.G. Capital
H.I.G. is a leading global alternative assets investment firm with over €35 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/value-added approach:
- H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
- H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
- H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of $30 billion. For more information, please refer to the H.I.G. website at www.higcapital.com .
* Based on total capital commitments managed by H.I.G. Capital and affiliates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005381/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
